Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
Leerink Partners analyst Thomas Smith initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $52.
Leerink Partners analyst Thomas Smith initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $52.